Language:

Oral Sodium Clodronate for Nonmetastatic Prostate Cancer—Results of a Randomized Double-Blind Placebo-Controlled Trial: Medical Research Council PR04 (ISRCTN61384873)

JNCI : Journal of the National Cancer Institute, 2007-05, Vol.99 (10), p.765-776 [Peer Reviewed Journal]

2007 The Author(s). 2007 ;2007 INIST-CNRS ;2007 The Author(s). ;ISSN: 0027-8874 ;EISSN: 1460-2105 ;DOI: 10.1093/jnci/djk178 ;PMID: 17505072 ;CODEN: JNCIEQ

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Oral Sodium Clodronate for Nonmetastatic Prostate Cancer—Results of a Randomized Double-Blind Placebo-Controlled Trial: Medical Research Council PR04 (ISRCTN61384873)
Author: Mason, Malcolm D. ; Sydes, Matthew R. ; Glaholm, John ; Langley, Ruth E. ; Huddart, Robert A. ; Sokal, Michael ; Stott, Mark ; Robinson, Anne C. ; James, Nicholas D. ; Parmar, Mahesh K. B. ; Dearnaley, David P.
Subjects: Administration, Oral ; Aged ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Bone Density Conservation Agents - administration & dosage ; Bone Density Conservation Agents - adverse effects ; Clinical trials ; Clodronic Acid - administration & dosage ; Clodronic Acid - adverse effects ; Combined Modality Therapy ; Disease Progression ; Double-Blind Method ; Drug therapy ; General and cellular metabolism. Vitamins ; Humans ; Kaplan-Meier Estimate ; Male ; Medical sciences ; Middle Aged ; Oncology ; Pharmacology. Drug treatments ; Prostate cancer ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - mortality ; Radiotherapy ; Tumors
Is Part Of: JNCI : Journal of the National Cancer Institute, 2007-05, Vol.99 (10), p.765-776
Description: Background The most frequent site of metastases from prostate cancer is bone. Adjuvant bisphosphonate treatment improves outcomes of patients with bone metastasis–negative breast cancer, but the effects of bisphosphonates on bone metastases in prostate cancer are not known. Methods We performed a randomized double-blind placebo-controlled trial to determine whether a first-generation bisphosphonate could improve symptomatic bone metastasis–free survival (time to symptomatic bone metastases or death from prostate cancer) in men with nonmetastatic prostate cancer who were at high risk of developing bone metastases. Between June 1, 1994, and December 31, 1997, 508 men from 26 UK sites and one New Zealand site who were within 3 years of initial prostate cancer diagnosis with no evidence of metastases from current bone scanning were randomly assigned to daily oral sodium clodronate (2080 mg/day, n = 254) or placebo (n = 254) for a maximum of 5 years. Estimates of outcome risks were compared using Kaplan–Meier analyses. Results The groups allocated to each treatment were well balanced. After a median follow-up of nearly 10 years, no evidence of benefit to the clodronate group was observed in terms of bone metastases–free survival (clodronate versus placebo, 80 events versus 68 events; hazard ratio [HR] = 1.22; 95% confidence interval [CI] = 0.88 to 1.68) or overall survival (clodronate versus placebo, 130 deaths versus 127 deaths; HR = 1.02; 95% CI = 0.80 to 1.30). Adverse events, notably gastrointestinal problems and increased lactate dehydrogenase levels, were more frequent in the clodronate group than in the placebo group; otherwise, clodronate was well tolerated. Modification of trial drug dose was more frequent in the clodronate group than the placebo group (HR = 1.63, 95% CI = 1.21 to 2.19). Conclusion Adjuvant sodium clodronate does not modify the natural history of nonmetastatic prostate cancer.
Publisher: Cary, NC: Oxford University Press
Language: English
Identifier: ISSN: 0027-8874
EISSN: 1460-2105
DOI: 10.1093/jnci/djk178
PMID: 17505072
CODEN: JNCIEQ
Source: Geneva Foundation Free Medical Journals at publisher websites
MEDLINE
Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Oral Sodium Clodronate for Nonmetastatic Prostate Cancer—Results of a Randomized Double-Blind Placebo-Controlled Trial: Medical Research Council PR04 (ISRCTN61384873)

2007 The Author(s). 2007 ;2007 INIST-CNRS ;2007 The Author(s). ;ISSN: 0027-8874 ;EISSN: 1460-2105 ;DOI: 10.1093/jnci/djk178 ;PMID: 17505072 ;CODEN: JNCIEQ

Searching Remote Databases, Please Wait